Results 31 to 40 of about 72,525 (247)

Impact of Rechallenge with Imatinib in Patients with Advanced Gastrointestinal Stromal Tumor after Failure of Imatinib and Sunitinib

Gastroenterology Research and Practice, 2014
Purpose. This retrospective, nonrandomized study investigated the effect of imatinib rechallenge plus best supportive care (BSC) on overall survival after imatinib and sunitinib treatment for patients with locally advanced or metastatic gastrointestinal ...
Akira Sawaki, Tatsuo Kanda, Yoshito Komatsu, Toshirou Nishida   +3 more
doaj   +1 more source

Imatinib Mesylate Reduces Neurotrophic Factors and pERK and pAKT Expression in Urinary Bladder of Female Mice With Cyclophosphamide-Induced Cystitis

Frontiers in Systems Neuroscience, 2022
Imatinib mesylate is a tyrosine kinase inhibitor that inhibits platelet-derived growth factor receptor (PDGFR)-α, -β, stem cell factor receptor (c-KIT), and BCR-ABL.
Megan Perkins, Beatrice M. Girard, Susan E. Campbell, Grant W. Hennig, Margaret A. Vizzard   +4 more
doaj   +1 more source

Rectal Gastrointestinal Stromal Tumor Poor Response to Imatinib: A Case Report. [PDF]

Clin Case Rep
ABSTRACT A 63‐year‐old man presented with persistent constipation lasting 6.5 months. Digital rectal examination revealed a soft‐tissue lesion near the anal verge without bleeding. Further evaluation identified a rectal mass. Treatment with imatinib for 6 months showed no significant response. The patient subsequently underwent surgical resection, with
Einakchi M, Samimi A, Zandbaf T, Mesbah N.   +3 more
europepmc   +2 more sources

CAQ Corner: Basic concepts of transplant immunology

, 2022
Liver Transplantation, EarlyView.
Amanda Cheung, Josh Levitsky
wiley   +1 more source

Treatment dilemmas in patients with gastrointestinal stromal tumors (GIST) who experienced imatinib-induced pneumonitis: A case series

Current Problems in Cancer: Case Reports
Introduction: Imatinib has led to a phenomenal progress in the treatment of GIST. A rare and lesser-known side effect of imatinib is pneumonitis, an uncommon multicausal interstitial lung disease.
Deborah van de Wal, Evelyne Roets, Roos F. Bleckman, Jorn Nützinger, Birthe C. Heeres, J. Martijn Kerst, Mahmoud Mohammadi, Anna K.L. Reyners, Ingrid M.E. Desar, Astrid W. Oosten, Neeltje Steeghs, Winette T.A. van der Graaf   +11 more
doaj   +1 more source

Determination of the Cut-off Value for Imatinib Plasma Levels Linked to Occurrence of Bone Pain in CML Patients

Drug Design, Development and Therapy, 2022
Marwa S Hamza,1 Samia A Shouman,2 Raafat Abdelfattah,3 Heba S Moussa,4 Mervat M Omran2 1Clinical Pharmacy Practice Department, Faculty of Pharmacy, The British University in Egypt, El-Sherouk City, Cairo, Egypt; 2Pharmacology Unit, Cancer Biology ...
Hamza MS, Shouman SA, Abdelfattah R, Moussa HS, Omran MM   +4 more
doaj  

Development of imatinibmesylate-induced interstitial lung disease 2 weeks after discontinuation of the treatment: a case report

Multidisciplinary Respiratory Medicine, 2012
Background Imatinibmesylate (imatinib) is a small molecule tyrosine kinase inhibitor administered to patients with chronic myelogenous leukemia and gastrointestinal stromal tumor.
Nakashima Shota, Kakugawa Tomoyuki, Motomura Hiroko, Hirano Katsuji, Sasaki Eisuke, Nagata Yasuhiro, Kinoshita Akitoshi, Sakamoto Noriho, Ishimatsu Yuji, Mukae Hiroshi, Kohno Shigeru   +10 more
doaj   +1 more source

Eradication of chronic myeloid leukemia stem cells: a novel mathematical model predicts no therapeutic benefit of adding G-CSF to imatinib [PDF]

, 2009
Imatinib mesylate induces complete cytogenetic responses in patients with chronic myeloid leukemia (CML), yet many patients have detectable BCR-ABL transcripts in peripheral blood even after prolonged therapy.
Holyoake, T., Tessa Holyoake, Michor Franziska, Michor, F., Holyoake Tessa, Clarkson Bayard, Foo, J., Mark W Drummond, Franziska Michor, Bayard Clarkson, Foo Jasmine, Drummond, M.W., Jasmine Foo, Clarkson, B., Drummond Mark W.   +14 more
core   +2 more sources

Identifying and validating a combined mRNA and microRNA signature in response to imatinib treatment in a chronic myeloid leukemia cell line. [PDF]

PLoS ONE, 2014
Imatinib, a targeted tyrosine kinase inhibitor, is the gold standard for managing chronic myeloid leukemia (CML). Despite its wide application, imatinib resistance occurs in 20-30% of individuals with CML.
Steven Bhutra, Divya Lenkala, Bonnie LaCroix, Meng Ye, R Stephanie Huang   +4 more
doaj   +1 more source

Six years survival on imatinib with no disease progression after diagnosis of metastatic duodenal gastrointestinal stromal tumour: a case report [PDF]

, 2008
Introduction: A duodenal Gastrointestinal Stromal Tumour (GIST) is a rare finding and until recently advanced disease had a poor prognosis. A PubMed search revealed no reports of more than five years survival of inoperable GIST on chemotherapy with WHO ...
Morrissey, John R., Bhattacharya Sayantan, Morrissey John, Choudhury Amit, Bhattacharya, Sayantan, Ravi, Srinivasan, Mathew, G. (George), Ravi Srinivasan, Mathew George, Choudhury, Amit Kumar   +9 more
core   +1 more source